The FDA released an update on its investigation of the association between GLP1RA use and suicidal risk. Credit: ormezz via Shutterstock

The US Food and Drug Administration (FDA) released an update on its evaluation of suicidal risk related to glucagon-like peptide-1 receptor agonists (GLP-1 RAs).

The agency did not find a clear link to suicidal risk through a review of reports of suicidal thoughts or actions received in the FDA Adverse Event Reporting System agency (FAERS) and a meta-analysis of GLP-1 RA clinical trials. Looking at FAERS data, regulators found that reported incidents were often limited in the information provided and did not offer enough evidence to determine a clear relationship with GLP-1 RA use. Furthermore, the large outcome studies and observational studies showed no association between suicidal thoughts or actions and the use of the drug class. Despite this, the agency said that due to the small number of suicidal ideation cases, it would not yet definitively rule out a potential link with GLP-1RA use. The FDA will share its conclusions upon completion of the assessment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The regulator urged patients to continue using GLP-1 RAs, per advice from their healthcare providers. The FDA also reminded healthcare professionals to monitor and advise patients using the drugs, checking, and reporting for “new or worsening depression, suicidal thoughts, or any unusual changes in mood or behaviour”, as per the 11 January update.

GLP-1 RAs are a class of drugs that help repair blood glucose control and minimise the risk of heart disease in patients with type 2 diabetes. These therapies are often also used in weight management for obesity. The drugs work by activating GLP-1 receptors in the pancreas, causing an increase in insulin release and reduced glucagon release. In November 2023, the FDA approved Eli Lilly’s Zepbound (tirzepatide) for weight management in obese or overweight patients, making it the 13th US approval within the drug class.

In July 2023, the European Medicines Agency (EMA) discussed its own ongoing review of the relationship between GLP-1RAs and suicidal thoughts. The review began after the Icelandic Medicines Agency flagged reports of suicidal thoughts and self-injury in patients on liraglutide and semaglutide. Drugs using these active ingredients include Novo Nordisk’s Ozempic and Saxenda. At the time of the announcement, the agency was investigating 150 reports of possible cases of self-injury and suicidal thoughts. In the same month, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) announced a similar probe reviewing suicidal risk associated with Ozempic and Saxenda.